Whitening Efficacy of Dentifrice Containing 10% High Cleaning Silica, 0.5% Sodium Phytate and 0.5% Sodium Pyrophosphate
CompletedNAResults postedLast updated 23 February 2022
What this trial tests
NA trial testing Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate in Tooth Bleaching in 86 participants. Completed in 5 October 2018.
Timeline
7 May 2018
Primary endpoint 28 September 2018
5 October 2018
Quick facts
Lead sponsor
Sun Yat-sen University
Phase
NA
Status
Completed
Study type
INTERVENTIONAL
Allocation
randomized
Design
parallel
Masking
double
Primary purpose
treatment
Enrollment
86
Start date
7 May 2018
Primary completion
28 September 2018
Estimated completion
5 October 2018
Sites
1 location across China
Drugs / interventions tested
Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate
Adults 18 to 64, any sex, with Tooth Bleaching. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Lobene Stain Index of Stain Extent Scores 4 Weeks After Dentifrice UsePrimary· 4 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The index measures the area and intensity of extrinsic tooth stain on the facial and lingual surfaces of the lower anterior teeth and facial surfaces of the upper anterior teeth. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain intensity was assessed using 0-3 scale. 0= No stain; 1=Light stain(yellow to light brown or gray); 2=Moderate stain(medium brown); 3=Heavy stain(dark brown to black).
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
1.35
± 0.6
Negative Control Toothpaste
1.64
± 0.65
Lobene Stain Index of Stain Area Scores 4 Weeks After Dentifrice UsePrimary· 4 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The index measures the area and intensity of extrinsic tooth stain on the facial and lingual surfaces of the lower anterior teeth and facial surfaces of the upper anterior teeth. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain area was assessed using 0-3 scale. 0= No stain detected; 1= stain covering up to 1/3 of the region; 2= Stain covering \>1/3 to 2/3 of the region; 3=Stain covering \>2/3 of the region.
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
1.1
± 0.44
Negative Control Toothpaste
1.32
± 0.47
Lobene Stain Index of Stain Composite Scores 4 Weeks After Dentifrice UsePrimary· 4 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain area was assessed using 0-3 scale and the stain intensity was assessed using 0-3 scale. Lobene Stain Index: Composite for each part is the product of the stain area and intensity scores. The minimum score for Lobene Stain Index: Composite is 0 when both the stain area and intensity scores are 0. The maximum score for Lobene Stain Index: Composite is 9 when both the stain area and intensity scores are 3.
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
2.39
± 1.35
Negative Control Toothpaste
3.23
± 1.6
Lobene Stain Index of Stain Extent Scores 8 Weeks After Dentifrice UsePrimary· 8 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The index measures the area and intensity of extrinsic tooth stain on the facial and lingual surfaces of the lower anterior teeth and facial surfaces of the upper anterior teeth. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain intensity was assessed using 0-3 scale. 0= No stain; 1=Light stain(yellow to light brown or gray); 2=Moderate stain(medium brown); 3=Heavy stain(dark brown to black).
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
0.98
± 0.49
Negative Control Toothpaste
1.33
± 0.68
Lobene Stain Index of Stain Area Scores 8 Weeks After Dentifrice UsePrimary· 8 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The index measures the area and intensity of extrinsic tooth stain on the facial and lingual surfaces of the lower anterior teeth and facial surfaces of the upper anterior teeth. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain area was assessed using 0-3 scale. 0= No stain detected; 1= stain covering up to 1/3 of the region; 2= Stain covering \>1/3 to 2/3 of the region; 3=Stain covering \>2/3 of the region.
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
0.83
± 0.36
Negative Control Toothpaste
1.12
± 0.46
Lobene Stain Index of Stain Composite Scores 8 Weeks After Dentifrice UsePrimary· 8 weeks after dentifrice use
Tooth stain of the anterior teeth were measured using the Lobene Stain Index. The tooth surfaces were divided into two parts: body and gingival. For each part, the stain area was assessed using 0-3 scale and the stain intensity was assessed using 0-3 scale. Lobene Stain Index: Composite for each part is the product of the stain area and intensity scores. The minimum score for Lobene Stain Index: Composite is 0 when both the stain area and intensity scores are 0. The maximum score for Lobene Stain Index: Composite is 9 when both the stain area and intensity scores are 3.
Group
Value
95% CI
Toothpaste Containing Effective Ingredients
1.45
± 0.78
Negative Control Toothpaste
2.5
± 1.52
Sponsor's own description
The objective of the present study was to compare the effects of a commercially available dentifrice containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate versus a negative control dentifrice on removal of extrinsic stains.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat
· Phase 2
· not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
· Phase 3
· not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
· Phase 2
· not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
· Phase 3
· recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 23 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04238429.